A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Phase 1
40
about 1.1 years
18+
3 sites in FL, NY, OH
About this study
This trial is testing a treatment combination of JNJ-86974680 and Pasritamig to see if it's safe and effective for people with advanced prostate cancer. The goal is to find the best dose of this combination that can be used in future studies.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take JNJ-86974680
- 2.Take Pasritamig
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of Participants With Adverse Events (AEs) by Severity, Part 1: Number of Participants With Dose-Limiting Toxicity (DLT)
Secondary: Duration of Response (DOR), Objective Response Rate (ORR), Prostate-Specific Antigen (PSA) Response Rate, Radiographic Progression-Free Survival (rPFS), Time to Response (TTR)
Oncology